| 영문 | protein | 한글 | 단백질 |
|---|---|---|---|
| 설명 | 탄소, 수소, 산소, 질소, 황을 함유하고 있는 유기화합물로, 모든 세포의 원형질을 이루고 있는 기본 구성물질이다. 단백질은 그 단위인 아미노산들이 펩티드결합에 의해 결합되어 있으며, 보통 20개의 아미노산들이 다른 순서와 조성을 가지고 배열되어, 독특한 하나의 단백질을 형성하게 된다. |
||
| 영문 | receptor | 한글 | 수용체 |
|---|---|---|---|
| 설명 | 세포질내 또는 세포표면에 존재하는 분자구조로서 특이물질과 선택적으로 결합하며 결합에 의해 특이한 생리적 작용을 나타낸다. 펩티드호르몬, 신경전달물질, 항원, 보체, 면역글로불린에 대한 세포표면 수용체와 스테로이드에 대한 세포질내 수용체가 있다. |
||
| 영문 | estrogen | 한글 | 에스트로겐 |
|---|---|---|---|
| 설명 | 난소안에 있는 난포에서 분비되는 난포호르몬의 총칭. 여포호르몬, 발정 호르몬이라고도 한다. 에스트로겐이란 생물학적인 명칭이며 동물의 발정작용 외에 여러 가지 작용을 지닌 물질의 총칭이다. 사람에는 20종 이상의 에스트로겐의 종류가 있지만, 그중에서도 estrone, estradiol, estriol의 3가지가 가장 중요하다. 에스트로겐은 비임신시에는 여포호르몬의 조절에 의해서, 주로 난소에서 생성되며, 임신시에는 주로 태반에서 만들어지지만, estriol은 태아의 부신과 태반의 합동작용에 의해서 만든다. 사람에게 있어서 에스트로겐의 주된 작용은 다음과 같은 것이 있다. 1. 제 2차 성징의 발현. 2. 내성기, 질, 외성기의 발육촉진 3. 자궁내막 및 성기 상피의 증식 4. 배란기에 자궁의 입구인 목에 점액을 증량시켜 정자의 통과성을 좋게 한다. 5. 임신시에 성기와 유방 등에 임신성 변화를 일으킨다. 6. 성기의 근육을 증식시켜 운동성을 증가시킨다. 7. 단백질 지질, 무기질 등의 물질대사나 여러 가지 효소의 작용에 영향을 준다. 8. 배란과 생리 주기의 유지에 관여한다. |
||
| ER | efficiency ratio; epigastric region; ejection rate; electroresection; emergency room; endoplasmic re... |
|---|---|
| ERP | early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr... |
| HCG, hCG | Human Chorionic Gonadotropin; 사람융모성성선자극호르몬 1. Placental Glycoprotein Hormone &nbs... |
| ERA | electrical response activity; electroencephalic response audiometry; Electroshock Research Associati... |
| ER | 1) Emergency Room; 응급실 2) Estrogen Receptor |
| ERP | Estrogen receptor protein |
|---|---|
| ER | Estrogen Receptor |
| ER-ICA | Estrogen receptor immunocytochemical assay |
| ER | Estrogen receptor alpha |
| ER alpha | Estrogen receptor alpha |
| estrogen | <endocrinology, hormone> A generic term for oestrus producing steroid compounds, the female sex hormones. In humans, oestrogen is formed in the ovary, possibly the adrenal cortex, the testis and the foetoplacental unit, it has various functions in both sexes. It is responsible for the development of the female secondary sex characteristics and during the menstrual cycle it acts on the female genitalia to produce an environment suitable for the fertilization, implantation and nutrition of the early embryo. Oestrogen is used in oral contraceptives and as a palliative in cancer of the breast after menopause and cancer of the prostate, other uses include the relief of the discomforts of menopause, inhibition of lactation and treatment of osteoporosis, threatened abortion and various functional ovarian disorders. (18 Nov 1997) |
|---|---|
| estrogen 2-hydroxylase | <enzyme> Same enzyme for hydroxylation in 2 or 4 position Registry number: EC 1.14.99.- Synonym: estrogen 4-hydroxylase, ethinylestradiol 2-hydroxylase (26 Jun 1999) |
| cAMP receptor protein | catabolite (gene) activator protein |
| receptor protein | An intracellular protein (or protein fraction) that has a high specific affinity for binding a known stimulus to cellular activity, such as a steroid hormone or adenosine 3',5'-cyclic phosphate. (05 Mar 2000) |
| receptor protein-tyrosine kinase | <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of receptors. Many growth and differentiation factor receptors contain this domain. It is critical for the signal transduction pathways required for mitogenesis, transformation, and cell differentiation. Registry number: EC 2.7.1.- (12 Dec 1998) |
| Cek4 receptor protein-tyrosine kinase | <enzyme> Isolated from mouse and chicken. Registry number: EC 2.7.1.- Synonym: cek4 protein, cek4 eph receptor, eph receptor cek4 (26 Jun 1999) |
| G-protein coupled receptor | <cell biology> Cell surface receptors that are coupled to G-proteins (GTP-binding protein). G-protein coupled receptors are thought to have seven membrane spanning domains and have been divided into 2 subclasses: those in which the binding site is in the extracellular domain for example receptors for glycoprotein hormones, such as thyroid stimulating hormone (TSH) and follicle-stimulating hormone (FSH) and those in which the ligand binding site is likely to be in the plane of the 7 transmembrane domains for example rhodopsin and receptors for small neurotransmitters and hormones for example muscarinic acetylcholine receptor. (18 Nov 1997) |
| cyclic AMP receptor protein | A transcriptional regulator in prokaryotes which, when activated by binding cyclic AMP, acts at several promoters. Cyclic AMP receptor protein was originally identified as a catabolite gene activator protein. It was subsequently shown to regulate several functions unrelated to catabolism, and to be both a negative and a positive regulator of transcription. Cell surface cyclic AMP receptors are not included (cyclic AMP receptors), nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins, which are the regulatory subunits of cyclic AMP-dependent protein kinases. (12 Dec 1998) |
| insulin receptor protein-tyrosine kinase | <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of the insulin receptor. Registry number: EC 2.7.1.- (12 Dec 1998) |
| insulin receptor substrate-1 protein | <chemical> Amino acid sequence given in first source; a 180 kD protein that contains multiple phosphorylated tyrosine residues after insulin stimulation; human and rat forms (hirs-1 and irs-1) are homologous Synonym: insulin receptor substrate-1-like protein, irs-1 protein, irs-1 gene product, hirs-1 protein, hirs-1 gene product, insulin receptor substrate 1, insulin receptor substrate-1 (05 Dec 1998) |
| TGF-beta receptor protein kinase | <enzyme> Belongs to the receptor-type serine-threonine kinase subfamily; from chick embryo, related to type II receptor for tgf-beta; 502 aa residues, mw 56,766 da; aa sequence given in first source Registry number: EC 2.7.1.- Synonym: tgf-beta rpk, rpk-1, rpk-2 (26 Jun 1999) |
| epidermal growth factor receptor protein-tyrosine kinase | <enzyme> The catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of epidermal growth factor receptor. Registry number: EC 2.7.1.- (12 Dec 1998) |
| light-repressible receptor protein kinase | <enzyme> Photo-regulated protein isolated from arabidopsis thaliana; genbank x97774 Registry number: EC 2.7.1.- Synonym: lrrpk gene product (26 Jun 1999) |
| acetylcholine receptor antibodies | <neurology, investigation> A test used to measure the amount of antibodies to acetylcholine receptors on nerve endings. This is a diagnostic test for myasthenia gravis. A normal value is no antibodies in the bloodstream. Acetylcholine receptor (AChR) binding autoantibodies (i.e. Antibodies reactive with several epitopes other than the binding site for acetylcholine or alpha-bungarotoxin) are present in approximately 88% of patients with generalised myasthenia gravis, 70% of ocular myasthenia and in approximately 80% of myasthenia gravis in remission. Although serum concentrations of AChR binding autoantibodies do not in general correlate well with severity of weakness, there is typical decrease in concentration as weakness improves with immunosuppressive therapy. AChR blocking autoantibodies (i.e., antibodies reactive with the AChR binding site) are present in about 50% of patients with myasthenia gravis, 30% with ocular myasthenia gravis and 20% of myasthenia gravis in remission, AChR blocking autoantibodies are the only AChR autoantibodies present in about 1% of myasthenia gravis. AChR modulating autoantibodies (i.e., autoantibodies which cross-link AChRs and cause their removal from muscle membrane surfaces) are present in more than 90% of myasthenia gravis and occasionally are the only AchR autoantibodies detectable in mild, recent onset or ocular-restricted myasthenia gravis. Results for AChR modulating autoantibodies can be transiently false-positive due to curare-like drugs used during general anesthesia. AChR autoantibodies of one or more types are found in at least 80% of ocular myasthenia gravis. Although generally absent in neurological conditions other than myasthenia gravis(and consequently unlikely to cause confusion in neurodiagnosis), false-positive results for AChR autoantibodies occasionally occur in primary biliary cirrhosis, tardive dyskinesia, autoimmune thyroiditis, the elderly, amyotrophic lateral sclerosis patients treated with cobra venom and patients with thymoma in the absence of myasthenia gravis. Approximately 1% of patients with rheumatoid arthritis treated with D-penicillamine develop AChR autoantibodies and myasthenia gravis, both of which disappear when the drug is discontinued. Babies born to ~10% of myasthenia gravis mothers have a transient neonatal form of myasthenia gravis that responds well to anticholinesterase therapy and usually remits within 1 month as maternal IgG disappears. (29 Dec 1997) |
| amino acid receptor | <biochemistry> Ligand gated ion channels with specific receptors for amino acid transmitters. An extended protein superfamily that also includes subunits of the nicotinic acetylcholine receptor. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|